PCLAF and atherosclerosis: It seems that the anti-inflammatory and anti-thrombotic anti-PAF properties of these yeast-derived polar lipid bioactives can subsequently reduce the risk for PAF-associated inflammatory chronic disorders, such as atherosclerosis, CVD, and cancer [6],[15],[16],[18], suggesting that these metabolites of S. cerevisiae are also promising candidates as ingredients for producing novel functional products with anti-inflammatory health-promoting effects.